RTTNews | Oct 8, 2021 09:01AM EDT

09:01 Friday, October 8, 2021 (RTTNews.com) - Shares of ChemoCentryx Inc (CCXI) have risen more than 72 percent in pre-market trading Friday, following FDA approval of the company's Avacopan.

Avacopan, under brand name Tavneos, has been approved as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis, specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) - the two main forms of ANCA vasculitis - in combination with standard therapy.

Anti-neutrophil cytoplasmic autoantibody-associated vasculitis, also known as ANCA-associated vasculitis or ANCA vasculitis is a rare autoimmune disease characterized by inflammation and destruction of small blood vessels, resulting in organ damage, particularly the kidneys.

Tavneos is expected to be made available to clinicians and patients in the next few weeks.

Roche's Rituximab is the only other FDA-approved therapy for adult patients with GPA and MPA. Tavneos has the potential to achieve blockbuster sales, according to analysts.

CCXI has traded in a range of $9.53-$70.29 in the past 52 weeks. It is currently trading in pre-market at $33.86, up $14.26 or 72.76 percent.

Read the original article on RTTNews ( https://www.rttnews.com/3231506/chemocentryx-secures-fda-nod-for-avacopan-shares-jump.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved